Investor Community Update – December 2025

Dec 15, 2025

Pirouette continues to make steady, meaningful progress toward bringing its auto-injector platform to patients, and the team is using the capital from our recent investment rounds to advance both regulatory and commercial readiness in a disciplined way. Over the past several months, the company has deepened its relationships with multiple large biopharmaceutical companies and strategic partners who are evaluating Pirouette's OnePush platform for use across rescue medicine, chronic disease, and next-generation metabolic therapies.

Strategic Collaborations

We are actively engaged in technical and commercial evaluations with global pharmaceutical companies and an industry-leading aerospace partner. These collaborators see OnePush as a way to enhance product differentiation, extend the life of important medicines, and unlock new channels such as retail, e-commerce, and mission-critical medical kits. While we cannot share names or financial terms yet, the depth and scope of these discussions continue to grow strong external validation of our platform's potential.

Regulatory Progress

Recent interactions with the U.S. Food and Drug Administration confirm that Pirouette is pursuing appropriate pathways for its lead programs, including potential over-the-counter use in select high-impact indications. These discussions have clarified key requirements for approval and informed refinements to study designs and device specifications. Our goal remains clear: enable simple, reliable self-injection for patients, first responders, and astronauts in environments where current delivery systems fall short.

Supply Chain Resilience

Due to recent tariffs impacting foreign suppliers for critical components like needles, springs, and tubing, we've taken proactive steps to strengthen our supply chain. Pirouette has successfully secured alternative domestic suppliers to keep us agile and resilient. These partnerships ensure we stay ahead of potential disruptions and maintain momentum as we scale.

Manufacturing Readiness

Pirouette is in late-stage discussions with experienced automation vendors to build a high-throughput, fully automated line for auto-injector production. This will ensure that, as products receive regulatory clearance, we can scale efficiently, maintain quality, and support both internal programs and partnered products. Early cost analyses suggest competitive unit costs at commercial volumes—critical for pricing flexibility and long-term margin expansion.

Growing Our Leadership Team

As we prepare for our Investigational New Drug (IND) application and clinical supply ramp-up, we're excited to announce new additions to our executive team. We recently added a Chief of Staff to enhance strategic alignment and operational efficiency across all functions.

Erin Beauregard, Chief of Staff

Erin Beauregard, MBA – Chief of Staff, Pirouette Pharma
Erin is a strategic business leader with extensive prior experience in finance, operations, strategy, and organizational transformation at global pharmaceutical companies, Pfizer and Takeda. As Chief of Staff at Pirouette Pharma, she partners with the executive team to accelerate growth by driving cross-functional alignment and advance the company's mission to reimagine the delivery of injectable medicines.

We're also recruiting a Vice President of Manufacturing and Vice President of Quality. These roles will ensure robust production capabilities and reinforce compliance and quality standards essential for regulatory success.

These additions reflect our dedication to building a strong foundation for growth and maturity. By expanding our leadership team, we are positioning the company to execute effectively on our IND submission and beyond, ensuring we meet the highest standards of excellence as we enter this pivotal phase.

Explore Our Updated Website

Visit Pirouettepharma.com to see how the OnePush platform is evolving across rescue medicine, chronic disease, and next-generation metabolic therapies. The site now offers an in-depth look at our technology, pipeline, and partnerships in a more accessible format, your best resource for ongoing progress and key developments.

Save the Date: Investor Webinar – 2025 Year in Review & 2026 Lookahead

We're closing out an incredible year at Pirouette and gearing up for an even bigger 2026. Join us for our Investor Webinar where we'll recap the major milestones that defined 2025 and share what's next as we accelerate toward regulatory approvals, clinical supply scale up, and strategic partnerships.

  • Date: Wednesday, January 7, 2026
  • Time: 2:00 PM EST
  • Location: Virtual (registration required)

Stay tuned for the registration link in the coming days. We can't wait to share how your support is shaping the future of the OnePush auto-injector platform.

The Pirouette team remains deeply grateful for your early support. We are committed to transparent communication while avoiding forward-looking promises about specific dates or revenue figures. The company believes it is meaningfully closer to key regulatory and partnership milestones than when this community first invested. Every day, we focus on converting today's technical and strategic momentum into future patient impact and long-term value for all stakeholders.

Conor R. Cullinane, Ph.D.
President & CEO
Pirouette Pharma Inc.

Background decoration

Get in touch

Reach out to learn more about Pirouette Pharma and explore partnerships.